<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02155582</url>
  </required_header>
  <id_info>
    <org_study_id>16790</org_study_id>
    <secondary_id>2013-004746-42</secondary_id>
    <nct_id>NCT02155582</nct_id>
  </id_info>
  <brief_title>Copanlisib Pharmacodynamic Study</brief_title>
  <official_title>A Phase I Pharmacodynamic Study of Copanlisib (BAY 80-6946) as Monotherapy in Patients With Non-Hodgkin's Lymphoma and Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to analyze what the study drug does to the body and its relationship to drug
      levels and safety after patients with advanced cancer have been treated with copanlisib in
      different dose groups.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 12, 2014</start_date>
  <completion_date type="Actual">March 16, 2017</completion_date>
  <primary_completion_date type="Actual">October 4, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum change from baseline in expression of pathway inhibition (pAKT) in surrogate tissue (platelet rich plasma) during copanlisib monotherapy</measure>
    <time_frame>Baseline and approximately 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum change from baseline in plasma glucose during 2 cycles of copanlisib monotherapy</measure>
    <time_frame>Baseline and after day 22</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC(0-168) of copanlisib after each copanlisib IV infusion during 2 cycles of copanlisib monotherapy</measure>
    <time_frame>After day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs as characterized by type, frequency, severity (as graded by CTCAE) and relationship to study drug</measure>
    <time_frame>Approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum change from baseline in insulin during 2 cycles of copanlisib</measure>
    <time_frame>After day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum change from baseline in C-peptide during 2 cycles of copanlisib</measure>
    <time_frame>After day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FDG PET early response (decreased SUVmax compared to baseline) after dosing with copanlisib for non-diabetic patients with detectable FDG tumor uptake at baseline</measure>
    <time_frame>After day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in expression and / or phosphorylation of PI3K pathway proteins in paired tumor biopsies</measure>
    <time_frame>Baseline and after day 22</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Non Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.8 mg/kg body weight and 0.4 mg/kg (not to exceed 65 mg) for the non-diabetic patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>45 mg and 60 mg for the diabetic patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Copanlisib (BAY80-6946)</intervention_name>
    <description>0.8 mg/kg body weight and 0.4 mg/kg (not to exceed 65 mg) for the non-diabetic patients;45 mg and 60 mg for the diabetic patients; Intravenous (IV) infusion over 1 hour. Dosing of copanlisib will be on Days 1, 8, and 15 of each 28 day treatment cycle.</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Histologically confirmed diagnosis of the following NHL: follicular lymphoma all
             grades, lymphoplasmacytic lymphoma / Waldenström macroglobulinemia, transformed
             indolent lymphoma, diffuse large B-cell lymphoma, Burkitt lymphoma, mantle cell
             lymphoma, or peripheral T-cell lymphoma, relapsed or refractory, with 1 or more prior
             chemo-immunotherapy- or immunotherapy-based regimen(s) OR

          -  Advanced and / or refractory solid tumors with high prevalence (≥30%) of PIK3CA or
             PTEN alteration: Breast and uterine cancers (endometrium cancers but also
             non-endometrial uterine cancers), lung (squamous cell only), cervical, head and neck,
             prostate, and ovarian cancers

          -  Biopsy-accessible tumor

          -  Male or female patients equal 18 or more years of age

          -  NHL patients must have at least 1 bi-dimensionally measurable lesion according to the
             modified Cheson criteria. Patients with solid tumors must have at least 1 solid tumor
             lesion measurable by computed tomography or magnetic resonance imaging according to
             the Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) criteria

          -  Eastern Cooperative Oncology Group performance status 2 or &lt;

          -  Life expectancy of at least 3 months

          -  Adequate bone marrow, liver, and renal functions as assessed by laboratory
             requirements conducted within 7 days before the first dose of study drug

          -  Left ventricular ejection fraction &gt; or equal the lower limit of normal for the
             institution

        Exclusion Criteria:

          -  Previous or concurrent cancer that is distinct in primary site or histology from NHL
             or the solid tumor, for which the patient is enrolled into this study, within 5 years
             before treatment start EXCEPT for curatively treated cervical cancer in situ,
             non-melanoma skin cancer, in situ breast cancer, in situ prostate carcinoma if Gleason
             score &lt; or equal to 6 and prostate-specific antigen &lt;10 ng/mL, and superficial bladder
             tumors [Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor invades lamina
             propria)]

          -  Known lymphomatous involvement of the brain or leptomeningeal involvement; solid tumor
             patients with central nervous system (CNS) metastases if treatment completed &lt;3 months
             before enrollment or lesions unstable or progressing on magnetic resonance imaging
             scans performed within 1 month of enrollment or unstable symptoms of the CNS
             metastases

          -  Any illness or medical condition that is unstable or could jeopardize the safety of
             the patient or his / her compliance in the study

          -  Current diagnosis of type 1 or type 2 diabetes mellitus with HbA1c &lt; or equal to 8.5%
             or fasting blood glucose &lt; or equal to 160 mg/dL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Bruxelles - Brussel</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles - Brussel</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Caen Cedex 5</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nice Cedex 2</city>
        <zip>06102</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2014</study_first_submitted>
  <study_first_submitted_qc>June 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2014</study_first_posted>
  <last_update_submitted>June 15, 2017</last_update_submitted>
  <last_update_submitted_qc>June 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

